A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change.

“There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues relegated to secondary importance,” explained Dr Richard Knight of ApconiX. “However, an improved safety profile is not only an important way to reduce the high rate of drug failure, it can also expedite clinical trials and, above all, it’s the best thing to do for patients.”

Read more here: Attitude toward safety in cancer drug development needs to change, says ApconiX co-founder